The global in-vivo optical imaging market is expanding due to the rising prevalence of chronic diseases, particularly cancer, with the global cancer incidence projected to reach 29.5 million new cases by 2040. This growth is further supported by the increasing demand for non-invasive diagnostic techniques in oncology, cardiology, and neurology. The market is also driven by advancements in drug development, especially in oncology and immunotherapy. North America leads the market, while Asia-Pacific shows significant growth due to improving healthcare access and awareness of advanced imaging technologies.
